SLPI Antibody [Unconjugated]

Western Blot shows lysates of mouse ovary. PVDF membrane was probed with 2 µg/ml of Goat Anti-Mouse SLPI Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1735) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for SLPI at approximately 12 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

The impact of SLPI on local response to LPS injection. (A) Total PEC number isolated from WT and Slpi-/- mice injected with PBS or LPS for 24h. (B) Peritoneal macrophage percentage and total number as in (A). (C) Representative gating for resident macrophages in WT and Slpi-/- mice injected with PBS or LPS for 24h.(D) SLPI expression in resident peritoneal macrophages isolated from WT (black line) and Slpi-/- mice (shaded histogram) injected with PBS or LPS for 24h.(E) Fold change of geometrical MFI was compared between WT and Slpi-/- macrophages as in (D). (F) MMP-9 in supernatants of WT and Slpi-/- total PEC or peritoneal adherent cells (macrophages) isolated from PBS or LPS injected mice and stimulated with LPS (100ng/ml) or HKLM (107 cells) for 24h.WT vs Slpi-/- **p<0.01 by multiple unpaired t-test. (A, B, E) Data represent 5 to 8 mice per experimental group pooled from three independent experiments. Error bars show means ± SEM. (F) Data represent 3 to 5 mice per experimental group pooled from two independent experiments. Error bars show means ± SEM. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/40496854), licensed under a CC-BY license. Not internally tested by R&D Systems.

LPS induces changes in expression pattern of SLPI in selected immune cell populations in vivo. (A) Total blood CD45+ leukocyte number isolated from WT and Slpi-/- mice injected with PBS or LPS for 24h. (B) Representative gating for neutrophils (CD11b+Ly6G+SiglecF-), eosinophils (CD11b+Ly6G-SiglecF+) and monocytes (CD11b+Ly6C+Ly6G-) as in (A). (C) Percentage of neutrophils, eosinophils and monocytes isolated as in (A). (D) Percentage of Ly6Chi, MHC II+F4/80+ and Ly6Clow monocytes isolated as in (A). (E) Representative gating of Ly6Chi (CD11b+Ly6Chigh), MHC II+F4/80+ and Ly6Clow monocytes isolated as in (A). (F, G) SLPI expression in blood neutrophils isolated from WT (black line) and Slpi-/- mice (shaded histogram) injected with PBS or LPS for 24h.Data represented as mean ± SEM of fold change in geometrical MFI values (WT vs Slpi-/-). (H) SLPI expression in blood monocytes represented as a fold change in geometrical MFI values (WT vs Slpi-/-). (I) Representative histograms of SLPI expression in blood monocytes isolated from WT (black line) and Slpi-/- mice (shaded histogram) injected with PBS or LPS for 24h. (A, C, D, F, H) Data represent 7 to 8 mice per experimental group pooled from three independent experiments Error bars show means ± SEM. (A, C, D, F) Control vs LPS or WT vs Slpi-/- * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by one-way ANOVA, Tukey post hoc test. (H) WT Ly6Chi monocytes vs WT Ly6Clow monocytes ****p<0.0001 by one-way ANOVA, Tukey post hoc test. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/40496854), licensed under a CC-BY license. Not internally tested by R&D Systems.

LPS induces changes in expression pattern of SLPI in selected immune cell populations in vivo. (A) Total blood CD45+ leukocyte number isolated from WT and Slpi-/- mice injected with PBS or LPS for 24h. (B) Representative gating for neutrophils (CD11b+Ly6G+SiglecF-), eosinophils (CD11b+Ly6G-SiglecF+) and monocytes (CD11b+Ly6C+Ly6G-) as in (A). (C) Percentage of neutrophils, eosinophils and monocytes isolated as in (A). (D) Percentage of Ly6Chi, MHC II+F4/80+ and Ly6Clow monocytes isolated as in (A). (E) Representative gating of Ly6Chi (CD11b+Ly6Chigh), MHC II+F4/80+ and Ly6Clow monocytes isolated as in (A). (F, G) SLPI expression in blood neutrophils isolated from WT (black line) and Slpi-/- mice (shaded histogram) injected with PBS or LPS for 24h.Data represented as mean ± SEM of fold change in geometrical MFI values (WT vs Slpi-/-). (H) SLPI expression in blood monocytes represented as a fold change in geometrical MFI values (WT vs Slpi-/-). (I) Representative histograms of SLPI expression in blood monocytes isolated from WT (black line) and Slpi-/- mice (shaded histogram) injected with PBS or LPS for 24h. (A, C, D, F, H) Data represent 7 to 8 mice per experimental group pooled from three independent experiments Error bars show means ± SEM. (A, C, D, F) Control vs LPS or WT vs Slpi-/- * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by one-way ANOVA, Tukey post hoc test. (H) WT Ly6Chi monocytes vs WT Ly6Clow monocytes ****p<0.0001 by one-way ANOVA, Tukey post hoc test. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/40496854), licensed under a CC-BY license. Not internally tested by R&D Systems.

LPS induces changes in expression pattern of SLPI in selected immune cell populations in vivo. (A) Total blood CD45+ leukocyte number isolated from WT and Slpi-/- mice injected with PBS or LPS for 24h. (B) Representative gating for neutrophils (CD11b+Ly6G+SiglecF-), eosinophils (CD11b+Ly6G-SiglecF+) and monocytes (CD11b+Ly6C+Ly6G-) as in (A). (C) Percentage of neutrophils, eosinophils and monocytes isolated as in (A). (D) Percentage of Ly6Chi, MHC II+F4/80+ and Ly6Clow monocytes isolated as in (A). (E) Representative gating of Ly6Chi (CD11b+Ly6Chigh), MHC II+F4/80+ and Ly6Clow monocytes isolated as in (A). (F, G) SLPI expression in blood neutrophils isolated from WT (black line) and Slpi-/- mice (shaded histogram) injected with PBS or LPS for 24h.Data represented as mean ± SEM of fold change in geometrical MFI values (WT vs Slpi-/-). (H) SLPI expression in blood monocytes represented as a fold change in geometrical MFI values (WT vs Slpi-/-). (I) Representative histograms of SLPI expression in blood monocytes isolated from WT (black line) and Slpi-/- mice (shaded histogram) injected with PBS or LPS for 24h. (A, C, D, F, H) Data represent 7 to 8 mice per experimental group pooled from three independent experiments Error bars show means ± SEM. (A, C, D, F) Control vs LPS or WT vs Slpi-/- * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by one-way ANOVA, Tukey post hoc test. (H) WT Ly6Chi monocytes vs WT Ly6Clow monocytes ****p<0.0001 by one-way ANOVA, Tukey post hoc test. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/40496854), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Mu
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

SLPI Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived mouse SLPI
• Specificity: Detects mouse SLPI in direct ELISAs and Western blots. In these formats, less than 5% cross-reactivity with recombinant human SLPI is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: SLPI
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
  *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for SLPI Antibody [Unconjugated]

• ALK1
• ALPProtease inhibitor WAP4
• antileukoproteinase
• BLPISeminal proteinase inhibitor
• HUSI
• HUSI-I
• Mucus proteinase inhibitor
• secretory leukocyte peptidase inhibitor
• secretory leukocyte protease inhibitor (antileukoproteinase)
• Secretory leukocyte protease inhibitor
• SLPI
• WAP four-disulfide core domain protein 4
• WAP4HUSI-1
• WFDC4MPI

Background

SLPI is a member of the Serpin family and is primarily expressed in secretory glandular epithelial cells. It is found in various secretory fluids and functions as a potent inhibitor of many proteolytic enzymes. SLPI can modulate cell proliferation and has been shown to have anti-inflammatory, anti-viral, and anti-bacterial activities (1, 2).

1. Zhang, D. et al. (2002) J. Biol. Chem. 277:29999.
2. Taggart, C.C. et al. (2002) J. Biol. Chem. 277:33648.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for SLPI Antibody (AF1735)(5)

Publications using AF1735

• Yu, Q;Tang, X;Hart, T;Homer, R;Belperron, AA;Bockenstedt, LK;Ring, A;Nakamura, A;Fikrig, E; Secretory leukocyte protease inhibitor influences periarticular joint inflammation in B. burgdorferi -infected mice bioRxiv : the preprint server for biology 2024-11-25 [PMID: 39651186] (Flow Cytometry, Immunocytochemistry)
• A Morimoto, J Kikuta, K Nishikawa, T Sudo, M Uenaka, M Furuya, T Hasegawa, K Hashimoto, H Tsukazaki, S Seno, A Nakamura, D Okuzaki, F Sugihara, A Ninomiya, T Yoshimura, R Takao-Kawa, H Matsuda, M Ishii SLPI is a critical mediator that controls PTH-induced bone formation Nature Communications, 2021-04-09;12(1):2136. 4/9/2021 [PMID: 33837198]
• Akinobu Ochi, Dong Chen, Wibke Schulte, Lin Leng, Nickolas Moeckel, Marta Piecychna et al. MIF-2/D-DT enhances proximal tubular cell regeneration through SLPI- and ATF4-dependent mechanisms American Journal of Physiology-Renal Physiology 2017-09-01 [PMID: 28539339]
• Sayers , Kevin T, Brooks , Alan D, Sayers , Thomas J, Chertov , Oleg Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells. PLoS ONE, 2014-08-11;9(8):e104223. 2014-08-11 [PMID: 25110884] (Western Blot, Mouse)
• Samsom JN, van der Marel AP, van Berkel LA, van Helvoort JM, Simons-Oosterhuis Y, Jansen W, Greuter M, Nelissen RL, Meeuwisse CM, Nieuwenhuis EE, Mebius RE, Kraal G Secretory leukoprotease inhibitor in mucosal lymph node dendritic cells regulates the threshold for mucosal tolerance. J. Immunol., 2007-11-15;179(10):6588-95. 2007-11-15 [PMID: 17982048] (Western Blot, Mouse)

Bioinformatics

• Gene Symbol: SLPI